中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

血清外纺锤体极样蛋白1(ESPL1)在HBV相关肝纤维化进程中的诊断价值

黄龙 梁红倩 任澳丽 苏明华 胡伯斌 黎清梅 苏土梅 殷倩冰 冯彦菲 江建宁

引用本文:
Citation:

血清外纺锤体极样蛋白1(ESPL1)在HBV相关肝纤维化进程中的诊断价值

DOI: 10.12449/JCH240911
基金项目: 

国家自然科学基金 (81960115);

国家自然科学基金 (82260124);

国家自然科学基金 (82160123);

区域性高发肿瘤早期防治研究教育部重点实验室自主研究项目 (GKE-ZZ202107);

广西区域性高发肿瘤早期防治研究重点实验室自主研究项目 (GKE-ZZ202218)

伦理学声明:本研究方案于2022年2月10日经由广西医科大学第一附属医院医学伦理委员会审批,批号:2022-KT-国基-142。
利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:黄龙参与设计,实施研究,采集数据,统计分析,文章撰写;苏明华、胡伯斌给予指导和支持;梁红倩、任澳丽、黎清梅、苏土梅、殷倩冰、冯彦菲负责患者随访,数据采集及分析;江建宁负责研究设计,数据分析,审阅和修改文章。
详细信息
    通信作者:

    江建宁, jjianning@163.com (ORCID: 0000-0001-8961-417X)

Diagnostic value of serum extra-spindle pole-like protein 1 in the progression of hepatitis B virus-related liver fibrosis

Research funding: 

National Natural Science Foundation of China (81960115);

National Natural Science Foundation of China (82260124);

National Natural Science Foundation of China (82160123);

Key Laboratory of High-Incidence-Tumor Prevention and Treatment (Guangxi Medical University), Ministry of Education (GKE-ZZ202107);

Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (GKE-ZZ202218)

More Information
    Corresponding author: JIANG Jianning, jjianning@163.com (ORCID: 0000-0001-8961-417X)
  • 摘要:   目的  探讨外纺锤体极样蛋白1(ESPL1)检测对HBV相关肝纤维化进程的临床诊断价值。  方法  选取2017年6月—2023年8月广西医科大学第一附属医院收治的HBV感染者228例,采用瞬时弹性成像系统FibroScan检测患者的肝硬度值(LSM),并根据LSM值分为无肝纤维化组(n=80)、轻度肝纤维化组(n=83)、进展期肝纤维化组(n=30)和肝硬化组(n=35)。采用酶联免疫吸附试验(ELISA)检测各组血清中的ESPL1水平。采用Kruskal-Wallis H检验比较4组患者血清ESPL1水平的差异;Spearman相关性分析方法比较ESPL1与LSM值的相关性;运用受试者工作特征(ROC)曲线分析血清ESPL1对不同肝纤维化进程的预测价值。  结果  肝硬化组血清ESPL1水平高于无肝纤维化组、轻度肝纤维化组(P值均<0.05),进展期肝纤维化组、轻度肝纤维化组血清ESPL1水平高于无肝纤维化组(P值均<0.05)。相关性分析显示:不同肝纤维化程度HBV感染者血清ESPL1与LSM值呈正相关(r=0.515,P<0.001);血清ESPL1预测肝硬化和进展期肝纤维化的曲线下面积分别为0.809和0.638,敏感度分别为87.5%和100%,特异度分别为59.7%和31.3%。  结论  血清ESPL1与HBV相关肝纤维化存在一定的相关性,血清ESPL水平越高可能提示肝纤维化程度越高;血清ESPL1可望成为辅助诊断肝硬化的血清标志物之一和动态监测HBV感染者肝纤维化进程的重要临床方法。

     

  • 图  1  各组患者血清中ESPL1水平

    Figure  1.  Serum ESPL1 levels of patients in each group

    图  2  CHB患者血清ESPL1与LSM值相关性散点图

    Figure  2.  Scatter diagram of correlation between serum ESPL1 and LSM values in CHB patients

    图  3  ESPL1诊断肝硬化效能的ROC曲线

    Figure  3.  Receiver operating characteristic curve of ESPL1 diagnostic efficacy for liver cirrhosis

    图  4  ESPL1诊断进展期肝纤维化效能的ROC曲线

    Figure  4.  Receiver operating characteristic curve of ESPL1 diagnostic efficacy for advanced liver fibrosis

    图  5  ESPL1诊断轻度肝纤维化效能的ROC曲线

    Figure  5.  Receiver operating characteristic curve of ESPL1 diagnostic efficacy for mild liver fibrosis

    表  1  患者一般资料表

    Table  1.   General information table of patients

    项目 无肝纤维化组(n=80) 轻度肝纤维化组(n=83) 进展期肝纤维化组(n=30) 肝硬化组(n=35) χ²值 P
    年龄(岁) 45±10 46±111) 49±8 53±102) 17.729 <0.05
    男[例(%)] 46(57.5) 69(83.1)2) 25(83.3)2) 25(71.4) 15.405 <0.05
    TBil(μmol/L) 14.7±5.8 17.1±7.4 17.2±9.3 23.3±15.22) 11.556 <0.05
    ALT(U/L) 19.8±7.0 23.9±8.72) 25.6±8.02) 25.1±8.12) 20.057 <0.05

    注:与肝硬化组比较,1)P<0.05;与无肝纤维化组比较,2)P<0.05。

    下载: 导出CSV
  • [1] FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48( 2): 335- 352. DOI: 10.1016/j.jhep.2007.11.011.
    [2] CHEN YC, CHU CM, LIAW YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology, 2010, 51( 2): 435- 444. DOI: 10.1002/hep.23348.
    [3] DUBERG AS, LYBECK C, FÄLT A, et al. Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study[J]. Hepatol Commun, 2022, 6( 9): 2418- 2430. DOI: 10.1002/hep4.1974.
    [4] Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j. issn.1001-5256.2019.10.007.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j. issn.1001-5256.2019.10.007.
    [5] Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Consensus on clinical application of transient elastography detecting liver fibrosis: A 2018 update[J]. Chin J Hepatol, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会, 等. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志, 2019, 27( 3): 182- 191. DOI: 10.3760/cma.j.issn.1007-3418.2019.03.004.
    [6] AGBIM U, ASRANI SK. Non-invasive assessment of liver fibrosis and prognosis: An update on serum and elastography markers[J]. Expert Rev Gastroenterol Hepatol, 2019, 13( 4): 361- 374. DOI: 10.1080/17474124.2019.1579641.
    [7] NEWSOME PN, SASSO M, DEEKS JJ, et al. FibroScan-AST(FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5( 4): 362- 373. DOI: 10.1016/S2468-1253(19)30383-8.
    [8] ZHANG X, ZHU GJ, YE XH, et al. Clinical value of GPR parameter model combined with Fibroscan for evaluating the stage of liver fibrosis in patientes with chronic hepatitis B[J]. Chin Hepatol, 2022, 27( 8): 877- 880. DOI: 10.14000/j.cnki.issn.1008-1704.2022.08.010.

    张鑫, 朱桂娟, 叶晓航, 等. GPR参数模型联合Fibroscan对慢性乙型肝炎肝纤维化的诊断效能[J]. 肝脏, 2022, 27( 8): 877- 880. DOI: 10.14000/j.cnki.issn.1008-1704.2022.08.010.
    [9] BACAC M, FUSCO C, PLANCHE A, et al. Securin and separase modulate membrane traffic by affecting endosomal acidification[J]. Traffic, 2011, 12( 5): 615- 626. DOI: 10.1111/j.1600-0854.2011.01169.x.
    [10] WANG RM, ZANG WW, HU BB, et al. Serum ESPL1 can be used as a biomarker for patients with hepatitis B virus-related liver cancer: A Chinese case-control study[J]. Technol Cancer Res Treat, 2020, 19: 1533033820980785. DOI: 10.1177/1533033820980785.
    [11] Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(2022 version)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
    [12] KANDA T, GOTO T, HIROTSU Y, et al. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: A review[J]. Int J Mol Sci, 2019, 20( 6): 1358. DOI: 10.3390/ijms20061358.
    [13] LAMPROYE A, BELAICHE J, DELWAIDE J. Le FibroScan: une nouvelle méthode d’évaluation non invasive de la fibrose hépatique[The FibroScan: a new non invasive method of liver fibrosis evaluation][J]. Rev Med Liege, 2007, 62 Spec No: 68- 72.
    [14] AKIMA T, TAMANO M, HIRAISHI H. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis[J]. Hepatol Res, 2011, 41( 10): 965- 970. DOI: 10.1111/j.1872-034X.2011.00846.x.
    [15] JEONG PY, KUMAR A, JOSHI PM, et al. Intertwined functions of separase and caspase in cell division and programmed cell death[J]. Sci Rep, 2020, 10( 1): 6159. DOI: 10.1038/s41598-020-63081-w.
    [16] SINGLETON MR, UHLMANN F. Separase-securin complex: A cunning way to control chromosome segregation[J]. Nat Struct Mol Biol, 2017, 24( 4): 337- 339. DOI: 10.1038/nsmb.3393.
    [17] WIRTH KG, WUTZ G, KUDO NR, et al. Separase: A universal trigger for sister chromatid disjunction but not chromosome cycle progression[J]. J Cell Biol, 2006, 172( 6): 847- 860. DOI: 10.1083/jcb.200506119.
    [18] RUPPENTHAL S, KLEINER H, NOLTE F, et al. Increased separase activity and occurrence of centrosome aberrations concur with transformation of MDS[J]. PLoS One, 2018, 13( 1): e0191734. DOI: 10.1371/journal.pone.0191734.
    [19] MUKHERJEE M, GE GQ, ZHANG NG, et al. Separase loss of function cooperates with the loss of p53 in the initiation and progression of T- and B-cell lymphoma, leukemia and aneuploidy in mice[J]. PLoS One, 2011, 6( 7): e22167. DOI: 10.1371/journal.pone.0022167.
    [20] JUNG KS, KIM SU, AHN SH, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement(FibroScan)[J]. Hepatology, 2011, 53( 3): 885- 894. DOI: 10.1002/hep.24121.
    [21] HU BB, WANG RM, LIANG HK, et al. Expression of ESPL1 gene in hepatocellular carcinoma tissue and its role in the prognosis assessment[J]. Chin Hepatol, 2023, 28( 3): 285- 289. DOI: 10.14000/j.cnki.issn.1008-1704.2023.03.008.

    胡伯斌, 王荣明, 梁蘅恺, 等. ESPL1基因在肝细胞癌组织中的表达及其在预后评估中的作用[J]. 肝脏, 2023, 28( 3): 285- 289. DOI: 10.14000/j.cnki.issn.1008-1704.2023.03.008.
    [22] DENG DL. Objective to evaluate the value of peripheral blood in the diagnosis of hepatocellular carcinoma and prediction of recurrence[D]. Nanning: Guangxi Medical University, 2021.

    邓德丽. 评估血清ESPL1对HBV相关肝细胞癌的诊断及预测复发的价值[D]. 南宁: 广西医科大学, 2021.
  • 加载中
图(5) / 表(1)
计量
  • 文章访问数:  51
  • HTML全文浏览量:  966
  • PDF下载量:  10
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-11-26
  • 录用日期:  2024-02-06
  • 出版日期:  2024-09-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回